SOMA and Baxter strike gene therapy deal

Precisely one year after a hoped-for strategic partnering deal fell through, Somatix Therapy Corp. has signed its first corporate deal, with Baxter Healthcare Corp., to develop a gene therapy approach for hemophilia.

Under the agreement, SOMA will develop a cell line that produces factor VIII or factor IX, and will use its

Read the full 529 word article

How to gain access

Continue reading with a
two-week free trial.